-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$5.00237.84% Upside
TCR2 Therapeutics Inc. Frequently Asked Questions
-
What analysts cover TCR2 Therapeutics Inc.?
TCR2 Therapeutics Inc. has been rated by research analysts at Goldman Sachs in the past 90 days.